<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308202">
  <stage>Registered</stage>
  <submitdate>10/07/2009</submitdate>
  <approvaldate>14/07/2009</approvaldate>
  <actrnumber>ACTRN12609000576224</actrnumber>
  <trial_identification>
    <studytitle>Observational Study and follow up of a Sepsis Biomarker for Sepsis Diagnosis in the Intensive Care</studytitle>
    <scientifictitle>Observational Study on the Efficacy of an Insulin Sensitivity-Based Sepsis Biomarker as a Diagnosis for the 
Severity of Sepsis in the Intensive Care and Long Term follow up</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Sepsis</healthcondition>
    <healthcondition>Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Baseline blood samples will be taken from all patients enrolled. Theses samples include electrolytes, arterial blood gas, complete blood count, C-reactive protein, lactate, Interluken-6 (IL-6), procalcitonin and oxidised protein sepsis markers.

Patients who are suspected to have sepsis (given antibiotics) and/or has systemic inflammatory response score (SIRS)&gt;=3 will have complete sepsis biomarkers blood tests. The complete sepsis biomarkers blood tests consist of blood samples taken at T=0 (time of onset of sickness), T=12 hrs, T=24 hrs, T=48 hrs and time of recovery (no sooner than T=72 hrs).

At T=0, blood samples are taken for bacterial cultural if suspected for sepsis, electrolytes, arterial blood gas, complete blood count, prothrombin ration, activated partial thromboplastin time (APTT), fibrinogen, C-reactive protein, lactate, Interluken-6 (IL-6), procalcitonin and oxidised protein sepsis markers. In addition, during the first hour, blood samples for insulin and c-peptide will be taken at T=0, 10, 40 and 60 mins.

At T=12 hrs, blood samples are taken for electrolytes, arterial blood gas, complete blood count, C-reactive protein, lactate, Interluken-6 (IL-6), procalcitonin and oxidised protein sepsis markers.

At T=24 hrs, blood samples are taken for bacterial cultural if suspected for sepsis, electrolytes, arterial blood gas, complete blood count, C-reactive protein, lactate, Interluken-6 (IL-6), procalcitonin and oxidised protein sepsis markers.

At T=48 hrs, blood samples are taken for electrolytes, arterial blood gas, complete blood count, C-reactive protein, Interluken-6 (IL-6), procalcitonin and oxidised protein sepsis markers.

Once patient recovers, defined as SIRS&lt;=2 for 6 hours after T=72 hrs or transferring out of ICU in &lt;=12 hours, blood samples are taken for electrolytes, arterial blood gas, complete blood count, C-reactive protein, Interluken-6 (IL-6), procalcitonin and oxidised protein sepsis markers. In addition, blood samples for insulin and c-peptide will be taken at T=0, 10, 40 and 60 mins from time of recovery.</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correlation between model-based and biological based sepsis biomarker and the 
severity of sepsis. The correlation will be calculated using a bivariate method. In addition, operating receiver characteristic (ROC) curve will be used to assess the sensitivity and specificity of the biomarkers.</outcome>
      <timepoint>baseline, T=0 hr when suspected sepsis and/or Systemic Inflammatory Response Score (SIRS)&gt;=3, T=12 hrs, T=24 hrs, T=48 hrs and time of recovery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of diabetes in patients who develop hyperglycaemia during their Intensive Care Unit (ICU) stay</outcome>
      <timepoint>2, 5 and 10 years after patient's stay in ICU</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Critically ill patients who are on the SPRINT glycaemic control protocol age &gt;=16 years</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Moribund or not expected to live for longer than 72 hours. Anticipated stay in ICU&lt;=48 hrs.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Intensive Care Unit, Christchurch Hospital</primarysponsorname>
    <primarysponsoraddress>Riccarton Avenue
Private Bag 4710
Christchurch</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Foundation of Research, Science and Technology</fundingname>
      <fundingaddress>Level 11, AT&amp;T Tower 
15 - 17 Murphy St 
Thorndon
Wellington 6144</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago Christchurch</sponsorname>
      <sponsoraddress>2 Riccarton Avenue, PO Box 4345
Christchurch 8140</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Canterbury</othercollaboratorname>
      <othercollaboratoraddress>Canterbury University 
Private Bag 4800 
Christchurch 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South B Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
4th Floor 250 Oxford Tce
PO Box 3877
Christchurch 8140</ethicaddress>
      <ethicapprovaldate>4/02/2009</ethicapprovaldate>
      <hrec>URB/08/12/059</hrec>
      <ethicsubmitdate>24/11/2008</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jessica Lin</name>
      <address>Department of Medicine
University of Otago Christchurch
2 Riccarton Avenue
PO Box 4345
Christchurch 8140</address>
      <phone>+64 3 3786305</phone>
      <fax />
      <email>jessica.lin@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jessica Lin</name>
      <address>Department of Medicine
University of Otago Christchurch
2 Riccarton Avenue
PO Box 4345
Christchurch 8140</address>
      <phone>+64 3 3786305</phone>
      <fax />
      <email>jessica.lin@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>